Investigation of abnomatily of cell cycle regulation and its clinical application in human lung cancer
Investigation of abnomatily of cell cycle regulation and its clinical application in human lung cancer
批准号:
11670191
负责人:
DOBASHI Yoh
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2001
中文摘要
为了探讨细胞周期调控的异常及其在肺癌中的临床应用,我们对肺癌手术标本进行了免疫组织化学染色和临床病理分析,2)对培养的肺癌细胞系进行了细胞生物学分析。1)细胞周期蛋白A的表达是增殖活性和患者预后不良的标志,II)肉瘤也是如此,III)细胞周期蛋白E的阳性也预示着腺癌的预后较差,但在鳞癌中预后较好,4)细胞周期蛋白E的阳性反映了非增殖细胞中蛋白质的积累,可能是细胞周期蛋白E降解下调的结果。2)从手术材料中建立了2个大细胞癌细胞系和3个小细胞癌细胞系,2)过表达cdc2或cdk2抑制PC12细胞的分化,3)同时下调cdc2和cdk2的活性,诱导PC12细胞分化;4)过表达CDK4诱导所有肺癌细胞系的凋亡。2的结果为肺癌的治疗提供了新的模式,通过给予细胞周期分子诱导细胞分化的凋亡来治疗肺癌。
英文摘要
To investigate the abnomatily of cell cycle regulation and its clinical application in human lung cancer, we performed 1) immunohistochemical staining with subsequent clinicopathological analysis on the surgical materials of lung cancer, 2) cell biological analysis using cultured cell lines of human lung cancer.1-I) expression of cyclin A serves as a marker of proliferative activity and patients' poor prognosis, ii) this was also true in sarcomoa, iii) cyclin E positivity also indicates worse prognosis in adenocarcinoma, but better prognosis in squamous cell carcinoma (SCC), iv) positivity of cyclin E in SCC reflects accumulation of protein in non-proliferating cells and may result from the downregulation of cyclin E degradation, iv) cdk-inhibitor serve as a assmbly factor for cyclin/cdk in low dose and activate its complex.2-I) Two cell lines of large cell carcinoma and 3 lines of small cell carcinoma were established from surgical materials, ii) overexpression of cdc2 or cdk2 suppressed differentiation of PC12 cells, iii) that simultaneous downregulation of cdc2 and cdk2 activity induces neuronal differentiation in PC12 cells iv) overexpression of cdk4 induced apoptosis in all cell lines of lung carcinoma.The results described in 1 showed diversity in the expression mechanism of cell cycle molecules depending on the histological type and utility of immunostaining of those protein for the evaluation of patients' prognosis in lung cancer. The results of 2 shed the light on the new mode of therapy for lung cancer by inducing apoptosis of cellular differentiation with administration of cell cycle molecules.
期刊论文(45)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Dobashi, Y., et al.: "CDK-inhibitors-associated kinase activity, a possible determinant of malignant potential in smooth muscle tumors of the soft tissue"Int. J. Cancer. 94(3). 353-362 (2001)
Dobashi, Y. 等人:“CDK 抑制剂相关激酶活性,软组织平滑肌肿瘤恶性潜能的可能决定因素”Int。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Noguchi,T.: "Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors."Am.J.Pathol.. 156(6). 2135-2147 (2000)
Noguchi,T.:“细胞周期蛋白参与细胞增殖及其在软组织平滑肌肿瘤中的临床意义。”Am.J.Pathol.. 156(6)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Dobashi, Y.: "A novel apoptotic cascade mediated by CDK4 in rat pheochromocytoma PC12 cells."Biochem. Biophys. Res. Comm.. 260. 806-812 (1999)
Dobashi, Y.:“大鼠嗜铬细胞瘤 PC12 细胞中由 CDK4 介导的新型凋亡级联。”Biochem。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Dobashi, Y.: "Simultaneous suppression of cdc2 and cdk2 activities induces neuronal differentiation of PC12 cells."J. Biol. chem.. (In press). (2000)
Dobashi, Y.:“同时抑制 cdc2 和 cdk2 活性可诱导 PC12 细胞的神经元分化。”J.
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Katayama, K., Dobashi, Y., et al.: "Overexpression of cdk4/cyclin D1 induces apoptosis in PC12 cells in the presence of trophic support"FEBS Lett.. 59(3). 382-388 (2001)
Katayama, K.、Dobashi, Y. 等人:“在存在营养支持的情况下,cdk4/cyclin D1 的过度表达会诱导 PC12 细胞凋亡”FEBS Lett.. 59(3)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 41 条
Involvement of Akt/mTOR in lung cancer and design of novel therapy targeting them
-
批准号:26460438
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.33万
-
财政年份:2014
-
负责人:DOBASHI Yoh
-
依托单位:
Aberrant activations of cellular kinases and exploration of novel targeted therapy in human solid cancers
-
批准号:23590409
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.41万
-
财政年份:2011
-
负责人:DOBASHI Yoh
-
依托单位:
Activation of signal transduction pathway by aberration of oncogenes : comprehensive analysis and application for multi-molecular targeting therapy
-
批准号:20590351
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.08万
-
财政年份:2008
-
负责人:DOBASHI Yoh
-
依托单位:
Aberrant activation of signal transduction pathways regulating cell proliieration in human slid tumors. Molecular-pathological analysis and clinical application of molecular targeting therapy.
-
批准号:18590327
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.47万
-
财政年份:2006
-
负责人:DOBASHI Yoh
-
依托单位:
Analyses for abnormality of cell cycle regulator molecules and their application to diagnosis and therapy in bone and soft tissue tumors
-
批准号:14570161
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.24万
-
财政年份:2002
-
负责人:DOBASHI Yoh
-
依托单位:
国内基金
海外基金
登录
查看更多内容
槐耳联合CDK4/6抑制剂调控Cyclin D1-CDK4/6-Rb通路在乳腺癌中的作用及机制研究
-
批准号:2026JJ82715
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:廖妮
-
依托单位:
青蒿琥酯调控Nrf2/HO-1-Cycin D1/CDK4-pRB信号轴诱导甲状腺相关眼病成纤维细胞衰老的机制研究
-
批准号:2025JJ60577
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:刘静远
-
依托单位:
靶向CDK7/cyclin H复合物的选择性小分子降解剂的设计合成与活性研究
-
批准号:22377013
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:林华
-
依托单位:
tRF-28-ZJ47D112Z4DZ通过Cyclin D1/CDK4抑制胃癌发生的机制及其早期诊断价值研究
-
批准号:82302611
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:俞秀冲
-
依托单位:
组蛋白去乙酰化酶抑制剂调控p21/Cyclin E/Rb信号通路逆转乳腺癌CDK4/6抑制剂耐药的作用及机制研究
-
批准号:82103013
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:王佳妮
-
依托单位:
CDK8通过活化Cyclin D1-NRF1信号通路促进胃癌恶性表型的作用及机制研究
-
批准号:82003080
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:周久力
-
依托单位:
蛋白激酶复合体Cdk12/cyclin k调控干细胞自我更新的分子机制研究
-
批准号:82071651
-
项目类别:面上项目
-
资助金额:52.0万元
-
批准年份:2020
-
负责人:肖雪
-
依托单位:
蛋白激酶复合体CDK12/cyclin K调控DNA复制的作用与机制研究
-
批准号:31971141
-
项目类别:面上项目
-
资助金额:54.0万元
-
批准年份:2019
-
负责人:李沁桐
-
依托单位:
Cyclin B2/CDK1通过APC/CCDH1调控卵母细胞减数分裂恢复的机制研究
-
批准号:31900593
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:李建
-
依托单位:
重楼皂苷I干预MAPK/Cyclin D1-CDK4/6/RB信号通路逆转乳腺癌耐药的作用和机制研究
-
批准号:81960739
-
项目类别:地区科学基金项目
-
资助金额:34.0万元
-
批准年份:2019
-
负责人:周轶平
-
依托单位: